Please login to the form below

Not currently logged in

Gilead and MacroGenics enter $1.7bn oncology partnership

The collaboration will focus on developing bispecific antibodies


Gilead Sciences (Gilead) has teamed up with MacroGenics – a biopharmaceutical company that specialises on the development and commercialisation of innovative monoclonal antibody-based therapeutics for the treatment of cancer – in a partnership focused on developing MGD024, an investigational, bispecific antibody.

The partnership will also involve two additional bispecific research programmes and details of the agreement allow Gilead the option to license MGD024, for use as a potential treatment for certain blood cancers, including acute myeloid leukaemia (AML) and myelodysplastic syndromes (MDS).

The financial details include MacroGenics receiving an upfront payment of $60m from Gilead, with the biopharma also eligible to receive up to $1.7bn in target nomination, option fees and development, regulatory and commercial milestones.

Moreover, MacroGenics will qualify for tiered, double-digit royalties on global net sales of MGD024, alongside a flat royalty on worldwide net sales of products under the two research programmes.

MGD024 is a next-generation, bispecific that incorporates a CD3 component that is designed to minimise cytokine-release syndrome (CRS) – a potentially life-threatening toxicity – while increasing the magnitude of antitumour activity with a longer half-life to allow for intermittent dosing.

With a background in developing novel therapeutics, MacroGenics offers the collaboration extensive experience having produced its proprietary DART platform.

Commenting on the new partnership, Gilead’s senior vice president, oncology and clinical development, Bill Grossman said: “MacroGenics’ bispecific expertise naturally complements Gilead’s portfolio strengths in immuno-oncology and our growing haematology franchise.

“We believe MGD024, with its potential to reduce CRS and permit intermittent dosing through a longer half-life, could translate to more patient-friendly dosing and enhanced clinical outcomes for people living with AML and MDS. This partnership is the latest in our efforts to develop and advance transformative new cancer therapies as we deepen our portfolio across oncology indications.”

According to the conditions of the agreement, MacroGenics will oversee the ongoing phase 1 study for MGD024 during which Gilead may elect to exercise its option to license the programme at predefined decision points.

Sharing his thoughts on the link-up, Scott Koenig, president and chief executive officer, MacroGenics said: “Rapid advances over the last decade have made CD123 a very promising target in oncology research. Advancing our bispecific DART molecule, MGD024, through a strategic collaboration with the team at Gilead will accelerate our ability to drive further development of MGD024 to the potential benefit of people living with blood cancers.”

Article by
Fleur Jeffries

18th October 2022

From: Research, Healthcare



Subscribe to our email news alerts

Featured jobs


Add my company
Create Health

A specialist Advertising and Med Comms agency dedicated to bringing much-needed creativity to healthcare marketing. We believe that brilliant ideas...

Latest intelligence

World Cancer Day 2023 – closing the gaps in cancer care to give more patients access to life-changing medicines
Great Expectations – exploring the counterpoint between advances in oncology and the challenges of ensuring life-changing medicines reach patients...
Strategic behaviour
Strong strategising depends on your colleagues’ behaviour...
Pharmaceutical Marketing Strategies For The Digital Age
In the digital age, a strong digital marketing strategy is crucial for businesses, especially in the highly competitive and complex pharmaceutical industry. There are key trends shaping pharmaceutical marketing, such...